Wim H.J. Kruit

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Alexander M.M. Eggermont, Stefan Suciu, Mario Santinami et al. · The Lancet · 2008 · 638 citations

Surgical Oncology, Medicine, Eortc 18991 +7

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Fernando Ulloa‐Montoya, Jamila Louahed, Benjamin Dizier et al. · Journal of Clinical Oncology · 2013 · 461 citations · Full text

Pretreatment Expression, Immunology, Immunoediting +20

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

Alexander M.M. Eggermont, Stefan Suciu, Rona M. MacKie et al. · The Lancet · 2005 · 310 citations

Surgical Oncology, Oncology, Melanoma +7

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Alexander M.M. Eggermont, Stefan Suciu, Alessandro Testori et al. · Journal of Clinical Oncology · 2012 · 279 citations · Full text

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Wim H.J. Kruit, Stefan Suciu, Brigitte Dréno et al. · Journal of Clinical Oncology · 2013 · 217 citations